US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
SYDNEY, Feb. 7, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a confirmation from the US Food and Drug Administration (FDA) that the diagnostic 64Cu...
Read more: US FDA Study May Proceed letter for Clarity's Cu-64 SAR-bisPSMA trial in prostate cancer